Developer docs
API playgroundTry for free, no card

Search company profiles

Dancann Pharma

Full company profile

uuid0000k2f

Namestring
Dancann Pharma
Legal namestring
DanCann Pharma A/S
Websiteurl
dancann.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

DanCann Pharma A/S is a Danish biopharmaceutical company founded in March 2018 by Jeppe Krog Rasmussen, headquartered in Ansager, Denmark, and listed on Sweden's Spotlight Stock Market (SS: DANCAN) since November 2020. The company historically operated across the full medicinal cannabis value chain — from EU-GMP-certified manufacturing at its BP1 facility, through importation and repackaging via its now-divested subsidiary CannGros ApS, to wholesale distribution to all Danish pharmacies — and held a portfolio of five standardized cannabis medicines (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) covering different cultivar profiles and a CBD-based formulation. Following an August 2023 strategic realignment and the November 2025 divestment of CannGros to Stenocare A/S in exchange for 5 million Stenocare shares (giving DanCann an ~11.5% stake), the operating footprint has materially contracted: the BP1 manufacturing site is under conditional sale (potential EUR 0.75M proceeds), the company is voluntarily delisting from Spotlight with last trading day expected January 22, 2026, and the new OTC Group ApS subsidiary (December 2024) signals a pivot toward over-the-counter preparations such as VitaZynq.

The business model is wholesale pharmaceutical distribution under Denmark's medicinal cannabis framework, with revenue generated from product sales to pharmacies (FY2024 net sales of DKK 7.76M, +27.8% YoY) at approximately DKK 250 per five-gram unit under the Danish reimbursement scheme, plus a developing OTC line. Go-to-market is B2B through Danish wholesalers serving pharmacies, with a separate practitioner-education channel (healthcare professional portal) to drive prescription demand. Customers are Danish pharmacies as direct buyers and, indirectly, chronic-pain patients (~1.3M Danes, 500,000 on opioid regimens) accessing treatment via physician prescription under the now-permanent Danish medicinal cannabis program. As of late 2025, the company's revenue base has been substantially transferred to Stenocare, and forward economics will depend on OTC Group buildout, residual licensing/IP economics, and value realization from the ~11.5% Stenocare equity stake.

Short descriptiontext

DanCann Pharma A/S is a Danish biopharmaceutical company that distributed standardized medicinal cannabis products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) to Danish pharmacies and now, following the November 2025 CannGros divestment, operates as a holding entity with an ~11.5% stake in Stenocare and a developing OTC cannabis subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAnsager, Denmark
HQ citystring
Ansager
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medicinal cannabis, cannabinoid pharmaceuticals, biopharmaceutical distribution, pharmaceutical manufacturing, cannabis-based therapeutics
Industry1 code
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Retail-Drug Stores And Proprietary Stores5912
Product category
Medicinal Cannabis Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medicinal Cannabis Product Sales
TypeTransaction Fee
Description

DanCann Pharma generates revenue through the sale of medicinal cannabis products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) to Danish pharmacies. The company reported net sales of DKK 7.76 million in 2024, up 27.8% year-over-year.

dancann.com
2Distribution and Sourcing Services
TypeTransaction Fee
Description

Following the 2023 strategic realignment, the company focuses on sourcing, distribution, and sales within the Danish market through its CannGros subsidiary. Revenue is generated from importation, repackaging, warehousing, logistics, and distribution of cannabis products to pharmacies.

dancann.com
3Shareholdings in Stenocare
TypeTransaction Fee
Description

Following the sale of CannGros to Stenocare A/S in November 2025, DanCann Pharma received 5,000,000 Stenocare shares (approximately 11.5% stake) as consideration, creating potential for equity value realization.

news.cision.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Medicinal cannabis products subsidized at approximately DKK 250 per five-gram unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products are subsidized at approximately DKK 250 per five-gram unit under the Danish medicinal cannabis scheme. Patients receive reimbursement for purchasing medicinal cannabis under the permanent scheme.

businessofcannabis.com
2Prescription-based medicinal cannabis through pharmacies
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Patients cannot order prescription-based medicinal cannabis directly from DanCann Pharma. Products can only be obtained at local pharmacies with a valid doctor's prescription. Pricing varies by product formulation.

dancann.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

DanCann Pharma manufactures and distributes standardized medicinal cannabis products for the Danish market, including flos and granule formulations (Bedrocan, Bedica, Bediol, Bedrolite, Bedrobinol) and oral extracts. The company sources, imports, repackages, and distributes these cannabis-based medicines to Danish pharmacies through its subsidiary CannGros ApS under the Danish Pilot Programme for Medicinal Cannabis. It also operates an EU-GMP certified production facility (BP1) and is developing OTC cannabinoid preparations through its OTC Group ApS subsidiary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Revenue growth of 27.8% YoY in 2024 (DKK 6.07M to DKK 7.76M)
+4 more records
Product overview1 text field

DanCann Pharma is a Danish biopharmaceutical company powered by cannabinoids, operating primarily as a distributor and manufacturer of medicinal cannabis products in Denmark. The company conducts its Danish operations through its subsidiary CannGros ApS, which handles importation, repackaging, warehousing, and distribution of cannabis products to all pharmacies across Denmark. The core product portfolio includes standardized cannabinoid medicines: Bedrocan®, Bedica®, Bediol®, Bedrolite®, and Bedrobinol® (flos/flower products and extracts). The company also has pipeline products including Bedrostract® (oral extract) and development-stage products like mouth spray formulations. In December 2024, the company established OTC Group ApS to expand into OTC preparations. The company's strategy (Maturity2028) has shifted toward distribution, sourcing, and import of medicinal cannabis following strategic realignment. Key recent developments include the sale of CannGros to Stenocare (November 2025) and plans to divest the BP1 production facility.

Product and service6 records
1Bedrocan
CategoryMedicinal Cannabis - Flos
Description

Standardized medicinal cannabis flower (flos) product, the brand name for the cultivar Cannabis Sativa L. 'Afina', distributed through the Danish Pilot Programme for patients with a valid doctor prescription.

2Bedica
CategoryMedicinal Cannabis - Flos
Description

Standardized medicinal cannabis flower (flos) product, the brand name for the indica cultivar Cannabis Sativa L. 'Talea', distributed through the Danish Pilot Programme.

3Bediol
CategoryMedicinal Cannabis - Flos/Granule
Description

Standardized medicinal cannabis product, the brand name for the cultivar Cannabis Sativa L. 'Elida', distributed through the Danish Pilot Programme.

4Bedrolite
CategoryMedicinal Cannabis - CBD Medicine
Description

Standardized CBD-based medicinal cannabis product, the brand name for the cultivar Cannabis Sativa L. 'Rensina', approved for the Danish medicinal cannabis market.

5Bedrobinol
CategoryMedicinal Cannabis - Flos
Description

Standardized medicinal cannabis flos product, the brand name for the cultivar Cannabis Sativa L. 'Ludina', approved for the Danish medicinal cannabis market.

6VitaZynq
CategoryOTC Cannabinoid Preparation
Description

Full-spectrum botanical (phyto) extract derived from Cannabis Sativa L., marketed as an over-the-counter (OTC) preparation through the OTC Group ApS subsidiary.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

DanCann Pharma divested its wholly-owned subsidiary CannGros ApS to StenoCare A/S through a share-for-share exchange. Stenocare issued 5,000,000 new shares to DanCann as consideration. This strategic transaction converts CannGros from an operating subsidiary into liquid listed equity, making DanCann one of the largest single shareholders in Stenocare (approximately 11.5%).

Strategic tierCoreTypeOthersAnnounced on2025-05-22
Description

DanCann Pharma received Danish Medicines Agency approval to launch Bedrolite and Bedrobinol products, expanding its medical cannabis portfolio to five offerings ahead of Denmark's permanent medical cannabis program.

Strategic tierMinorTypeOthersAnnounced on2025-02-01
Description

DanCann Pharma is represented through its membership in MCI, where CEO Jeppe Krog Rasmussen serves as Vice Chairman of the interest organization. MCI serves as a reference group for medicinal cannabis extended through 2025-2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

DanCann Pharma acquired CannGros ApS in October 2021 as a strategic move to overtake distribution of Bedrocan, Bediol, and Bedica products to all pharmacies in Denmark. CannGros was subsequently sold to Stenocare in November 2025.

Strategic tierCoreTypeOthersAnnounced on2018-06-01
Description

DanCann secured the first license from the Danish Medicines Agency under the Development Scheme for handling cannabis for medical purposes, becoming among the first companies granted such a license.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Ayruma AG (formerly Northern Green Canada / CC Pharma)
TypeRegional player
Description

European-focused cannabis pharmaceutical distribution company with German pharmacy distribution roots; comparable B2B distribution of medical cannabis to retail pharmacies under regulatory schemes.

TypeEmerging player
Description

Israeli manufacturer of pharmaceutical-grade cannabinoid medicines with EU-GMP compliant production; comparable cannabis-based pharmaceutical formulations and dosage-form development focus.

TypeBroad incumbent
Description

Canadian global cannabis company with European medical cannabis operations including cultivation, manufacturing and distribution of EU-GMP certified products across multiple European markets including Denmark-adjacent geographies.

TypeDirect peer
Description

German medicinal cannabis distribution platform that partners with international producers to bring standardized cannabis medicines to German pharmacies. Highly comparable GTM: B2B pharmacy distribution of third-party-produced standardized cannabis medicines.

TypeBroad incumbent
Description

Canadian global cannabis incumbent with Spectrum Therapeutics medical cannabis portfolio distributed in European markets, including Germany and other countries following similar reimbursement pathways.

TypeDirect peer
Description

German producer and distributor of medical cannabis flowers and extracts under EU-GMP, serving a parallel pharmaceutical-distribution model in Europe's largest medicinal cannabis pilot market.

TypeEmerging player
Description

Canadian pharmaceutical-grade cannabis producer with EU-GMP certification supplying wholesale cannabis APIs and finished dose formats to European distributors; comparable role in the medicinal cannabis supply chain.

8Tilray Brands Inc.
TypeBroad incumbent
Description

Large Canadian-headquartered global cannabis player with established EU medical cannabis operations including cultivation in Portugal and Germany, distributing branded medical cannabis products through European pharmacy channels.

TypeDirect peer
Description

Dutch producer of standardized medicinal cannabis flos that supplies the Bedrocan, Bediol, Bedica, Bedrolite and Bedrobinol products DanCann distributes. Same product family, same regulatory pathway (EU-GMP), same patient base across Europe.

TypeDirect peer
Description

Danish medicinal cannabis company listed on Spotlight Stock Market; acquired DanCann's CannGros subsidiary in November 2025, making DanCann an 11.5% shareholder. Operates in the same Danish pilot/permanent programme with overlapping product portfolios including the patented ASTRUM oil.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dancann Pharma

Medicinal Cannabis Pharmaceuticalsdancann.com

DanCann Pharma A/S is a Danish biopharmaceutical company that distributed standardized medicinal cannabis products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) to Danish pharmacies and now, following the November 2025 CannGros divestment, operates as a holding entity with an ~11.5% stake in Stenocare and a developing OTC cannabis subsidiary.

What Dancann Pharma does

DanCann Pharma A/S is a Danish biopharmaceutical company founded in March 2018 by Jeppe Krog Rasmussen, headquartered in Ansager, Denmark, and listed on Sweden's Spotlight Stock Market (SS: DANCAN) since November 2020. The company historically operated across the full medicinal cannabis value chain — from EU-GMP-certified manufacturing at its BP1 facility, through importation and repackaging via its now-divested subsidiary CannGros ApS, to wholesale distribution to all Danish pharmacies — and held a portfolio of five standardized cannabis medicines (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) covering different cultivar profiles and a CBD-based formulation. Following an August 2023 strategic realignment and the November 2025 divestment of CannGros to Stenocare A/S in exchange for 5 million Stenocare shares (giving DanCann an ~11.5% stake), the operating footprint has materially contracted: the BP1 manufacturing site is under conditional sale (potential EUR 0.75M proceeds), the company is voluntarily delisting from Spotlight with last trading day expected January 22, 2026, and the new OTC Group ApS subsidiary (December 2024) signals a pivot toward over-the-counter preparations such as VitaZynq.

The business model is wholesale pharmaceutical distribution under Denmark's medicinal cannabis framework, with revenue generated from product sales to pharmacies (FY2024 net sales of DKK 7.76M, +27.8% YoY) at approximately DKK 250 per five-gram unit under the Danish reimbursement scheme, plus a developing OTC line. Go-to-market is B2B through Danish wholesalers serving pharmacies, with a separate practitioner-education channel (healthcare professional portal) to drive prescription demand. Customers are Danish pharmacies as direct buyers and, indirectly, chronic-pain patients (~1.3M Danes, 500,000 on opioid regimens) accessing treatment via physician prescription under the now-permanent Danish medicinal cannabis program. As of late 2025, the company's revenue base has been substantially transferred to Stenocare, and forward economics will depend on OTC Group buildout, residual licensing/IP economics, and value realization from the ~11.5% Stenocare equity stake.

Dancann Pharma firmographics

Firmographics
Name
Dancann Pharma
Legal name
DanCann Pharma A/S
Website
https://dancann.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
DanCann Pharma A/S is a Danish biopharmaceutical company that distributed standardized medicinal cannabis products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) to Danish pharmacies and now, following the November 2025 CannGros divestment, operates as a holding entity with an ~11.5% stake in Stenocare and a developing OTC cannabis subsidiary.
Ownership category
akta.pro rank

Dancann Pharma industry classification

Industry
Product category
Medicinal Cannabis Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Medicinal Chemicals & Botanical Products (2833), Retail-Drug Stores And Proprietary Stores (5912)
akta.pro industry
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Medicinal cannabis
  • Cannabinoid pharmaceuticals
  • Biopharmaceutical distribution
  • Pharmaceutical manufacturing
  • Cannabis-based therapeutics

Where Dancann Pharma is headquartered

Location

Headquarters

HQ city
Ansager
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

Dancann Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Medicinal Cannabis Product Sales: DanCann Pharma generates revenue through the sale of medicinal cannabis products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) to Danish pharmacies. The company reported net sales of DKK 7.76 million in 2024, up 27.8% year-over-year.
  2. Distribution and Sourcing Services: Following the 2023 strategic realignment, the company focuses on sourcing, distribution, and sales within the Danish market through its CannGros subsidiary. Revenue is generated from importation, repackaging, warehousing, logistics, and distribution of cannabis products to pharmacies.
  3. Shareholdings in Stenocare: Following the sale of CannGros to Stenocare A/S in November 2025, DanCann Pharma received 5,000,000 Stenocare shares (approximately 11.5% stake) as consideration, creating potential for equity value realization.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goMedicinal cannabis products subsidized at approximately DKK 250 per five-gram unit
Unit PricingPay-as-you-goPrescription-based medicinal cannabis through pharmacies

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Dancann Pharma product offering

Product offering

Core offering

DanCann Pharma manufactures and distributes standardized medicinal cannabis products for the Danish market, including flos and granule formulations (Bedrocan, Bedica, Bediol, Bedrolite, Bedrobinol) and oral extracts. The company sources, imports, repackages, and distributes these cannabis-based medicines to Danish pharmacies through its subsidiary CannGros ApS under the Danish Pilot Programme for Medicinal Cannabis. It also operates an EU-GMP certified production facility (BP1) and is developing OTC cannabinoid preparations through its OTC Group ApS subsidiary.

Product overview

DanCann Pharma is a Danish biopharmaceutical company powered by cannabinoids, operating primarily as a distributor and manufacturer of medicinal cannabis products in Denmark. The company conducts its Danish operations through its subsidiary CannGros ApS, which handles importation, repackaging, warehousing, and distribution of cannabis products to all pharmacies across Denmark. The core product portfolio includes standardized cannabinoid medicines: Bedrocan®, Bedica®, Bediol®, Bedrolite®, and Bedrobinol® (flos/flower products and extracts). The company also has pipeline products including Bedrostract® (oral extract) and development-stage products like mouth spray formulations. In December 2024, the company established OTC Group ApS to expand into OTC preparations. The company's strategy (Maturity2028) has shifted toward distribution, sourcing, and import of medicinal cannabis following strategic realignment. Key recent developments include the sale of CannGros to Stenocare (November 2025) and plans to divest the BP1 production facility.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bedrocan Standardized medicinal cannabis flower (flos) product, the brand name for the cultivar Cannabis Sativa L. 'Afina', distributed through the Danish Pilot Programme for patients with a valid doctor prescription.
  • Bedica Standardized medicinal cannabis flower (flos) product, the brand name for the indica cultivar Cannabis Sativa L. 'Talea', distributed through the Danish Pilot Programme.
  • Bediol Standardized medicinal cannabis product, the brand name for the cultivar Cannabis Sativa L. 'Elida', distributed through the Danish Pilot Programme.
  • Bedrolite Standardized CBD-based medicinal cannabis product, the brand name for the cultivar Cannabis Sativa L. 'Rensina', approved for the Danish medicinal cannabis market.
  • Bedrobinol Standardized medicinal cannabis flos product, the brand name for the cultivar Cannabis Sativa L. 'Ludina', approved for the Danish medicinal cannabis market.
  • VitaZynq Full-spectrum botanical (phyto) extract derived from Cannabis Sativa L., marketed as an over-the-counter (OTC) preparation through the OTC Group ApS subsidiary.

Quantifiable outcome

  • Revenue growth of 27.8% YoY in 2024 (DKK 6.07M to DKK 7.76M)
  • +4 more outcomes

Companies that use Dancann Pharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Dancann Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Dancann Pharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • StenoCare A/ScoreStrategic or Co-development Partner · 17 November 2025DanCann Pharma divested its wholly-owned subsidiary CannGros ApS to StenoCare A/S through a share-for-share exchange. Stenocare issued 5,000,000 new shares to DanCann as consideration. This strategic transaction converts CannGros from an operating subsidiary into liquid listed equity, making DanCann one of the largest single shareholders in Stenocare (approximately 11.5%).
  • Danish Medicines AgencycoreOthers · 22 May 2025DanCann Pharma received Danish Medicines Agency approval to launch Bedrolite and Bedrobinol products, expanding its medical cannabis portfolio to five offerings ahead of Denmark's permanent medical cannabis program.
  • Medicinsk Cannabis Industri (MCI)minorOthers · 1 February 2025DanCann Pharma is represented through its membership in MCI, where CEO Jeppe Krog Rasmussen serves as Vice Chairman of the interest organization. MCI serves as a reference group for medicinal cannabis extended through 2025-2026.
  • CannGros ApScoreStrategic or Co-development Partner · 1 October 2021DanCann Pharma acquired CannGros ApS in October 2021 as a strategic move to overtake distribution of Bedrocan, Bediol, and Bedica products to all pharmacies in Denmark. CannGros was subsequently sold to Stenocare in November 2025.
  • Danish Medicines AgencycoreOthers · 1 June 2018DanCann secured the first license from the Danish Medicines Agency under the Development Scheme for handling cannabis for medical purposes, becoming among the first companies granted such a license.

Scale indicators12 records

Recent moves10 records

Expansion highlights5 records

Dancann Pharma competitors and assessment

Company assessment

Regional players

  • Ayruma AG (formerly Northern Green Canada / CC Pharma): European-focused cannabis pharmaceutical distribution company with German pharmacy distribution roots; comparable B2B distribution of medical cannabis to retail pharmacies under regulatory schemes.

Emerging players

  • Panaxia Labs Israel Industries: Israeli manufacturer of pharmaceutical-grade cannabinoid medicines with EU-GMP compliant production; comparable cannabis-based pharmaceutical formulations and dosage-form development focus.
  • MediPharm Labs Corp. Canadian pharmaceutical-grade cannabis producer with EU-GMP certification supplying wholesale cannabis APIs and finished dose formats to European distributors; comparable role in the medicinal cannabis supply chain.

Broad incumbents

  • Aurora Cannabis Inc. Canadian global cannabis company with European medical cannabis operations including cultivation, manufacturing and distribution of EU-GMP certified products across multiple European markets including Denmark-adjacent geographies.
  • Canopy Growth Corporation: Canadian global cannabis incumbent with Spectrum Therapeutics medical cannabis portfolio distributed in European markets, including Germany and other countries following similar reimbursement pathways.
  • Tilray Brands Inc. Large Canadian-headquartered global cannabis player with established EU medical cannabis operations including cultivation in Portugal and Germany, distributing branded medical cannabis products through European pharmacy channels.

Direct peers

  • Cantourage GmbH: German medicinal cannabis distribution platform that partners with international producers to bring standardized cannabis medicines to German pharmacies. Highly comparable GTM: B2B pharmacy distribution of third-party-produced standardized cannabis medicines.
  • Demecan GmbH: German producer and distributor of medical cannabis flowers and extracts under EU-GMP, serving a parallel pharmaceutical-distribution model in Europe's largest medicinal cannabis pilot market.
  • Bedrocan BV: Dutch producer of standardized medicinal cannabis flos that supplies the Bedrocan, Bediol, Bedica, Bedrolite and Bedrobinol products DanCann distributes. Same product family, same regulatory pathway (EU-GMP), same patient base across Europe.
  • Stenocare A/S: Danish medicinal cannabis company listed on Spotlight Stock Market; acquired DanCann's CannGros subsidiary in November 2025, making DanCann an 11.5% shareholder. Operates in the same Danish pilot/permanent programme with overlapping product portfolios including the patented ASTRUM oil.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Dancann Pharma social profiles

Digital presence

Dancann Pharma compliance and trust

Trust signal

Compliance3 records

Dancann Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dancann Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Dancann Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Dancann Pharma funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dancann Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dancann Pharma

What does Dancann Pharma do?

DanCann Pharma manufactures and distributes standardized medicinal cannabis products for the Danish market, including flos and granule formulations (Bedrocan, Bedica, Bediol, Bedrolite, Bedrobinol) and oral extracts. The company sources, imports, repackages, and distributes these cannabis-based medicines to Danish pharmacies through its subsidiary CannGros ApS under the Danish Pilot Programme for Medicinal Cannabis. It also operates an EU-GMP certified production facility (BP1) and is developing OTC cannabinoid preparations through its OTC Group ApS subsidiary.

Is Dancann Pharma a public or private company?

Dancann Pharma is a public company. It is classified as public and is currently operating.

When was Dancann Pharma founded?

Dancann Pharma was founded in 2018. It employs 1 to 10 people.

Where is Dancann Pharma based?

Dancann Pharma is headquartered in Ansager, Denmark, in the Europe region.

How does Dancann Pharma make money?

Three revenue lines are on record. Medicinal Cannabis Product Sales are the primary driver. The others are distribution and Sourcing Services and shareholdings in Stenocare.

Who are Dancann Pharma's main competitors?

Ayruma AG (formerly Northern Green Canada / CC Pharma) is listed as a regional player. Emerging players are Panaxia Labs Israel Industries and MediPharm Labs Corp.. Broad incumbents are Aurora Cannabis Inc., Canopy Growth Corporation and Tilray Brands Inc.. Direct peers are Cantourage GmbH, Demecan GmbH, Bedrocan BV and Stenocare A/S.

Does Dancann Pharma have an API?

No public API is recorded for Dancann Pharma.

What industry is Dancann Pharma in?

Dancann Pharma's product category is Medicinal Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comDanCann Pharma A/S: Extraordinary exercise period for warrants commences today as a result application for delistingDanCann Pharma A/S, a Danish biopharmaceutical company, announced an extraordinary exercise period for 1,224,993 outstanding warrants effective December 29, 2025, following shareholder approval on October 21, 2025, for the company's voluntary delisting from Spotlight Stock Market. The delisting application will be submitted on January 7, 2026, with the last trading day expected to be January 22, 2026, and warrant holders can exercise at DKK 2.60 per share until January 12, 2026. The delisting is triggered under the warrant terms as an "Exit" event, which permits warrant holders to exercise their rights ahead of the delisting.StenocareSTENOCAREStenocare A/S has entered into a share purchase agreement to acquire 100% of CannGros ApS from DanCann Pharma A/S, executed as a share-for-share exchange where Stenocare issues 5,000,000 new shares to DanCann. The acquisition expands Stenocare's Danish medical cannabis portfolio from four oil-based products to nine products total by adding CannGros's five approved flower-based products, making Stenocare the leading supplier across both categories. The company expects the acquisition to generate approximately DKK 4–6 million in annual revenue from 2026 onward and support its goal of reaching break-even in 2026, with the share issuance creating an 11.6% dilution for existing shareholders.MarketScreenerDancann Pharma Shares Moved to Spotlight's Observation ListTrading in Dancann Pharma shares will be moved to Spotlight Stock Market's observation list following a transaction announced on November 17. Dancann Pharma sold its entire stake in its subsidiary Canngros to Stenocare through a share swap deal, with Stenocare issuing 5 million new shares as payment, resulting in Dancann owning 11.5 percent of Stenocare. The move to the observation list is a standard administrative action by the marketplace triggered by the disclosed transaction.news.cision.comCorrection of total shares issued and total nominal share capital:Stenocare A/S has entered into a share purchase agreement to acquire 100% of CannGros ApS from DanCann Pharma A/S through a share-for-share exchange of 5,000,000 newly issued Stenocare shares. The acquisition expands Stenocare's Danish product portfolio from four to nine approved medical cannabis products and is expected to generate approximately DKK 4–6 million in annual revenue from 2026 onwards while supporting the company's goal of reaching break-even. With this transaction, Stenocare becomes the leading supplier of both oil-based and flower-based medical cannabis products in Denmark, with DanCann Pharma becoming a major shareholder with 11.52% stake.news.cision.comDanCann Pharma A/S delivers Q3 2025 Highlights – Leadership Transition, Strategic Progress, and Path Toward DelistingDanCann Pharma A/S reported its Q3 2025 financial results, showing operational progress, strategic transformation, and organizational leadership changes. The company experienced a quarterly increase in sales and improved EBITDA while preparing for delisting from the Spotlight Stock Market.news.cision.comMinutes of Extraordinary General Meeting held in DanCann Pharma A/SDanCann Pharma A/S held an extraordinary general meeting on 21 October 2025 in Ansager, Denmark, where shareholders unanimously approved the board's resolution to voluntarily delist the company's shares from Spotlight Stock Market. The board expects to submit the delisting application on 7 January 2026, with the last trading day expected on 22 January 2026, after which shares will trade over-the-counter. The amendments to the articles of association enable the delisting and ensure the shares remain freely transferable after leaving the exchange.news.cision.comDanCann Pharma A/S shares supplementary details of the obtained bridge loanDanCann Pharma A/S announced a bridge loan of DKK 2 million from ten investors, including its largest shareholder JEQ Capital AB. The loan carries a 15% upfront fee and 2% monthly fee, with conversion at DKK 1.13 per share. The company may repay early with 10-day notice.news.cision.comDanCann Pharma A/S signs a conditional sales agreement for the sale of manufacturing site (BP1), secures bridge financing, and launches new strategy, Maturity2028DanCann Pharma signed a conditional sales agreement for its production facility BP1 at EUR 1.25 million, securing DKK 2 million in bridge financing. The company will receive net proceeds of about EUR 0.75 million and has launched its Maturity2028 strategy, including a group structure and name change to DCP Group.TradingViewDanCann Pharma A/S signs a conditional sales agreement for the sale of manufacturing site (BP1), secures bridge financing, and launches new strategy, Maturity2028DanCann Pharma signed a conditional sales agreement to sell its production facility BP1 for EUR 1.25 million, with net proceeds of about EUR 0.75 million. The company secured a DKK 2 million bridge loan and launched its Maturity2028 strategy, including a name change to DCP Group.